Chlorpromazine and Signifor
Determining the interaction of Chlorpromazine and Signifor and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using pasireotide together with chlorproMAZINE can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: Pasireotide can cause bradycardia and QT prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In healthy study subjects given therapeutic (0.6 mg twice daily) and supratherapeutic (1.95 mg twice daily) dosages of pasireotide, the maximum mean placebo-subtracted QTcI change from baseline was 12.7 msec and 16.6 msec, respectively. Both dosages decreased heart rate, with a maximum mean placebo-subtracted change from baseline of -10.9 beats per minute (bpm) observed at 1.5 hours for the therapeutic dosage and -15.2 bpm at 0.5 hours for the supratherapeutic dosage. The mean steady-state peak plasma concentration (Cmax) produced by the supratherapeutic dosage was 3.3-fold that observed with the therapeutic dosage. In clinical studies of patients with Cushing's disease, two of 201 patients experienced single occurrences of QTcF exceeding 500 msec. Torsade des pointes arrhythmias were not observed in these or other studies. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).
MANAGEMENT: Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting pasireotide therapy and periodically during treatment in accordance with the product labeling. Hypokalemia and hypomagnesemia must be corrected prior to pasireotide administration. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals, East Hanover, NJ.
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
Generic Name: chlorpromazine
Brand name: Ormazine, Thorazine, Thorazine Spansule
Synonyms: ChlorproMAZINE
Generic Name: pasireotide
Brand name: Signifor, Signifor LAR
Synonyms: Signifor Injection
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Chlorpromazine-Signifor (Pasireotide Extended-Release Injection)
- Chlorpromazine-Signifor (Pasireotide Injection)
- Chlorpromazine-Signifor Injection
- Chlorpromazine-Signifor LAR
- Chlorpromazine-Signifor LAR Injection
- Chlorpromazine-Siklos
- Signifor-Chlorpromazine Hydrochloride
- Signifor-Chlorpromazine Injection
- Signifor-Chlorpromazine Tablets
- Signifor-Chlorpropamide
- Signifor-ChlorTan
- Signifor-ChlorTan D